Ars Pharmaceuticals Inc (SPRY) returns
Ars Pharmaceuticals returns over 5 years
$1,000 invested in Ars Pharmaceuticals five years ago was worth $391.66 at the close on October 30, 2026, with dividends reinvested: an average return of -17.1% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -21.6% | — | $784.22 | -0.9% |
| 3 months | -40.0% | — | $600.36 | +2.1% |
| Year to date | -71.0% | — | $290.13 | +11.7% |
| 1 year | -60.8% | — | $392.11 | +12.4% |
| 3 years | -2.9% | -1.0% | $971.26 | +88.5% |
| 5 years | -60.8% | -17.1% | $391.66 | +76.0% |
Ars Pharmaceuticals return by calendar year
| Year | SPRY | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -71.0% | +11.7% | -82.7% |
| 2025 | +10.4% | +17.7% | -7.3% |
| 2024 | +92.5% | +24.9% | +67.6% |
| 2023 | -35.8% | +26.2% | -61.9% |
| 2022 | +28.1% | -18.2% | +46.2% |
| 2021 | -85.6% | +28.7% | -114.4% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: SPRY financials
No forecast, no recommendation. This page describes Ars Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.